BofA lowered the firm’s price target on Amylyx (AMLX) to $15 from $16 and keeps a Buy rating on the shares after the company reported Q3 earnings and confirmed a cash runway to 2028 due to recent financing. The “driver of the story” remains pivotal Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia expected in Q3 of 2026, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Positive Buy Rating for Amylyx Pharmaceuticals Based on Promising Phase I LUMINA Study Results and Strategic Advancements
- Amylyx price target raised to $18 from $16 at Mizuho
- Amylyx price target raised to $20 from $16 at H.C. Wainwright
- Amylyx Pharmaceuticals Reports Strong Q3 2025 Results
- Amylyx Pharmaceuticals: Positive Earnings Call Highlights Progress and Challenges